Pharmacological and electrophysiological characterization of nine, single nucleotide polymorphisms of the hERG-encoded potassium channel

British Journal of Pharmacology

Volumn 159, Issue 1, 2010, Pages 102-114

  Mannikko R ^a   Overend, G ^a   Perrey, C ^a   Gavaghan, C L ^b   Valentin, J P ^a   Morten, J ^a   Armstrong, M ^a   Pollard, C E ^a  

^a ASTRAZENECA   (United Kingdom)

^b ASTRAZENECA R AND D   (Sweden)

Author keywords

Electrophysiology; HERG; Pharmacology; QT interval prolongation; Safety margins; Single nucleotide polymorphisms; Torsades de Pointes

Indexed keywords

POTASSIUM CHANNEL HERG; PROPAFENONE;

ANIMAL CELL; ARTICLE; AUTOMATION; BINDING AFFINITY; BINDING SITE; CONTROLLED STUDY; DRUG POTENCY; ELECTRIC POTENTIAL; ELECTROPHYSIOLOGY; GENE EXPRESSION; GENE FREQUENCY; GENE MUTATION; GENE SEQUENCE; GENETIC VARIABILITY; IC 50; NONHUMAN; PHYSICAL CHEMISTRY; POPULATION RESEARCH; PRIORITY JOURNAL; SINGLE NUCLEOTIDE POLYMORPHISM; VALIDATION STUDY;

ANIMALS; CHO CELLS; CRICETINAE; CRICETULUS; ELECTROPHYSIOLOGY; ETHER-A-GO-GO POTASSIUM CHANNELS; EUROPEAN CONTINENTAL ANCESTRY GROUP; HUMANS; INHIBITORY CONCENTRATION 50; PHARMACEUTICAL PREPARATIONS; POLYMORPHISM, SINGLE NUCLEOTIDE;

EID: 74549219313     PISSN: 00071188     EISSN: 14765381     Source Type: Journal    
DOI: 10.1111/j.1476-5381.2009.00334.x     Document Type: Article

References (57)

1. Abbott GW, Sesti F, Splawski I, Buck ME, Lehmann MH, Timothy KW et al. (1999). MiRP1 forms IKr potassium channels with hERG and is associated with cardiac arrhythmia. Cell 97 : 175 187.
2. Ackerman MJ, Tester DJ, Jones GS, Will ML, Burrow CR, Curran ME (2003). Ethnic differences in cardiac potassium channel variants: implications for genetic susceptibility to sudden cardiac death and genetic testing for congenital long QT syndrome. Mayo Clin Proc 78 : 1479 1487.
3. Alexander SP, Mathie A, Peters JA (2008). Guide to receptors and channels (GRAC), 3rd edition. Br J Pharmacol 153 (Suppl. 2 S1 S209.
4. Anon 2005a). The clinical evaluation of QT/QTc interval prolongation and proarrhythmic potential for non-antiarrhythmic drugs. ICH E14 CHMP/ICH/2/04.
5. Anon 2005b). The nonclinical evaluation of the potential for delayed ventricular repolarisation (QT interval prolongation) by human pharmaceuticals. ICH S7B CHMP/ICH/423/02.
6. Anson BD, Ackerman MJ, Tester DJ, Will ML, Delisle BP, Anderson CL et al. (2004). Molecular and functional characterization of common polymorphisms in hERG (KCNH2) potassium channels. Am J Physiol Heart Circ Physiol 286 : H2434 H2441.
7. Aydin A, Bahring S, Dahm S, Guenther UP, Uhlmann R, Busjahn A et al. (2005). Single nucleotide polymorphism map of five long-QT genes. J Mol Med 83 : 159 165.
8. Bellocq C, Wilders R, Schott JJ, Louerat-Oriou B, Boisseau P, Le Marec H et al. (2004). A common antitussive drug, clobutinol, precipitates the long QT syndrome 2. Mol Pharmacol 66 : 1093 1102.
9. Bezanilla F, Armstrong CM (1977). Inactivation of the sodium channel. I. Sodium current experiments. J Gen Physiol 70 : 549 566. (Pubitemid 8239321)
10. Bridgland-Taylor MH, Hargreaves AC, Easter A, Orme A, Henthorn DC, Ding M et al. (2006). Optimisation and validation of a medium-throughput electrophysiology-based hERG assay using IonWorks HT. J Pharmacol Toxicol Methods 54 : 189 199.
11. Cavero I, Mestre M, Guillon JM, Crumb W (2000). Drugs that prolong QT interval as an unwanted effect: assessing their likelihood of inducing hazardous cardiac dysrhythmias. Expert Opin Pharmacother 1 : 947 973.
12. Chapman H, Pasternack M (2007). The action of the novel gastrointestinal prokinetic prucalopride on the hERG K(+) channel and the common T897 polymorph. Eur J Pharmacol 554 : 98 105.
13. Crotti L, Lundquist AL, Insolia R, Pedrazzini M, Ferrandi C, De Ferrari GM et al. (2005). KCNH2-K897T is a genetic modifier of latent congenital long-QT syndrome. Circulation 112 : 1251 1258.
14. De Bruin ML, Pettersson M, Meyboom RH, Hoes AW, Leufkens HG (2005). Anti-hERG activity and the risk of drug-induced arrhythmias and sudden death. Eur Heart J 26 : 590 597.
15. Fodstad H, Bendahhou S, Rougier JS, Laitinen-Forsblom PJ, Barhanin J, Abriel H et al. (2006). Molecular characterization of two founder mutations causing long QT syndrome and identification of compound heterozygous patients. Ann Med 38 : 294 304.
16. Ford GA, Wood SM, Daly AK (2000). CYP2D6 and CYP2C19 genotypes of patients with terodiline cardiotoxicity identified through the yellow card system. Br J Clin Pharmacol 50 : 77 80.
17. Iwasa H, Itoh T, Nagai R, Nakamura Y, Tanaka T (2000). Twenty single nucleotide polymorphisms (SNPs) and their allelic frequencies in four genes that are responsible for familial long QT syndrome in the Japanese population. J Hum Genet 45 : 182 183.
18. Jones EM, Roti Roti EC, Wang J, Delfosse SA, Robertson GA (2004). Cardiac IKr channels minimally comprise hERG 1a and 1b subunits. J Biol Chem 279 : 44690 44694.
19. Jongbloed R, Marcelis C, Velter C, Doevendans P, Geraedts J, Smeets H (2002). DHPLC analysis of potassium ion channel genes in congenital long QT syndrome. Hum Mutat 20 : 382 391.
20. Kang J, Wang L, Chen XL, Triggle DJ, Rampe D (2001). Interactions of a series of fluoroquinolone antibacterial drugs with the human cardiac K+ channel hERG. Mol Pharmacol 59 : 122 126.
21. Kirsch GE, Trepakova ES, Brimecombe JC, Sidach SS, Erickson HD, Kochan MC et al. (2004). Variability in the measurement of hERG potassium channel inhibition: effects of temperature and stimulus pattern. J Pharmacol Toxicol Methods 50 : 93 101.
22. Kiss L, Bennett PB, Uebele VN, Koblan KS, Kane SA, Neagle B et al. (2003). High throughput ion-channel pharmacology: planar-array-based voltage clamp. Assay Drug Dev Technol 1 : 127 135.
23. Kupershmidt S, Yang IC, Hayashi K, Wei J, Chanthaphaychith S, Petersen CI et al. (2003). The IKr drug response is modulated by KCR1 in transfected cardiac and noncardiac cell lines. FASEB J 17 : 2263 2265.
24. Laitinen P, Fodstad H, Piippo K, Swan H, Toivonen L, Viitasalo M et al. (2000). Survey of the coding region of the HERG gene in long QT syndrome reveals six novel mutations and an amino acid polymorphism with possible phenotypic effects. Hum Mutat 15 : 580 581.
25. Larsen LA, Andersen PS, Kanters J, Svendsen IH, Jacobsen JR, Vuust J et al. (2001). Screening for mutations and polymorphisms in the genes KCNH2 and KCNE2 encoding the cardiac hERG/MiRP1 ion channel: implications for acquired and congenital long Q-T syndrome. Clin Chem 47 : 1390 1395.
26. Linna EH, Perkiomaki JS, Karsikas M, Seppanen T, Savolainen M, Kesaniemi YA et al. (2006). Functional significance of KCNH2 (HERG) K897T polymorphism for cardiac repolarization assessed by analysis of T-wave morphology. Ann Noninvasive Electrocardiol 11 : 57 62.
27. Mank-Seymour AR, Richmond JL, Wood LS, Reynolds JM, Fan YT, Warnes GR et al. (2006). Association of torsades de pointes with novel and known single nucleotide polymorphisms in long QT syndrome genes. Am Heart J 152 : 1116 1122.
28. Männikkö R, Harmer AR, Overend G, Perrey C, Valentin JP, Morten J et al. 2006). Pharmacological characterisation of 9 single nucleotide polymorphisms (SNPs) of the hERG-encoded K channel. Proc Physiol Soc 8 : PC10.
29. Milnes JT, Crociani O, Arcangeli A, Hancox JC, Witchel HJ (2003). Blockade of hERG potassium currents by fluvoxamine: incomplete attenuation by S6 mutations at F656 or Y652. Br J Pharmacol 139 : 887 898.
30. Mitcheson JS, Perry MD (2003). Molecular determinants of high-affinity drug binding to hERG channels. Curr Opin Drug Discov Devel 6 : 667 674.
31. Oprea TI, Gottfries J (2001). Chemography: the art of navigating in chemical space. J Comb Chem 3 : 157 166.
32. Paavonen KJ, Chapman H, Laitinen PJ, Fodstad H, Piippo K, Swan H et al. (2003). Functional characterization of the common amino acid 897 polymorphism of the cardiac potassium channel KCNH2 (hERG). Cardiovasc Res 59 : 603 611.
33. Paulussen AD, Gilissen RA, Armstrong M, Doevendans PA, Verhasselt P, Smeets HJ et al. (2004). Genetic variations of KCNQ1, KCNH2, SCN5A, KCNE1, and KCNE2 in drug-induced long QT syndrome patients. J Mol Med 82 : 182 188.
34. Redfern WS, Carlsson L, Davis AS, Lynch WG, MacKenzie I, Palethorpe S et al. (2003). Relationships between preclinical cardiac electrophysiology, clinical QT interval prolongation and torsade de pointes for a broad range of drugs: evidence for a provisional safety margin in drug development. Cardiovasc Res 58 : 32 45.
35. Saenen JB, Paulussen AD, Jongbloed RJ, Marcelis CL, Gilissen RA, Aerssens J et al. (2007). A single hERG mutation underlying a spectrum of acquired and congenital long QT syndrome phenotypes. J Mol Cell Cardiol 43 : 63 72.
36. Sale H, Wang J, O'Hara TJ, Tester DJ, Phartiyal P, He JQ et al. (2008). Physiological properties of hERG 1a/1b heteromeric currents and a hERG 1b-specific mutation associated with Long-QT syndrome. Circ Res 103 : e81 e95.
37. Sanguinetti MC, Tristani-Firouzi M (2006). hERG potassium channels and cardiac arrhythmia. Nature 440 : 463 469.
38. Schroeder K, Neagle B, Trezise DJ, Worley J (2003). Ionworks HT: a new high-throughput electrophysiology measurement platform. J Biomol Screen 8 : 50 64.
39. Sesti F, Abbott GW, Wei J, Murray KT, Saksena S, Schwartz PJ et al. (2000). A common polymorphism associated with antibiotic-induced cardiac arrhythmia. Proc Natl Acad Sci USA 97 : 10613 10618.
40. Shah RR (2005). Drugs, QT interval prolongation and ICH E14: the need to get it right. Drug Saf 28 : 115 125.
41. Shuraih M, Ai T, Vatta M, Sohma Y, Merkle EM, Taylor E et al. (2007). A common SCN5A variant alters the responsiveness of human sodium channels to class I antiarrhythmic agents. J Cardiovasc Electrophysiol 18 : 434 440.
42. Simard C, Drolet B, Yang P, Kim RB, Roden DM (2005). Polymorphism screening in the cardiac K+ channel gene KCNA5. Clin Pharmacol Ther 77 : 138 144.
43. Smith PL, Baukrowitz T, Yellen G (1996). The inward rectification mechanism of the hERG cardiac potassium channel. Nature 379 : 833 836.
44. Splawski I, Shen J, Timothy KW, Lehmann MH, Priori S, Robinson JL et al. (2000). Spectrum of mutations in long-QT syndrome genes. KVLQT1, hERG, SCN5A, KCNE1, and KCNE2. Circulation 102 : 1178 1185.
45. Sun Z, Milos PM, Thompson JF, Lloyd DB, Mank-Seymour A, Richmond J et al. (2004). Role of a KCNH2 polymorphism (R1047 L) in dofetilide-induced Torsades de Pointes. J Mol Cell Cardiol 37 : 1031 1039.
46. Swan H, Viitasalo M, Piippo K, Laitinen P, Kontula K, Toivonen L (1999). Sinus node function and ventricular repolarization during exercise stress test in long QT syndrome patients with KvLQT1 and hERG potassium channel defects. J Am Coll Cardiol 34 : 823 829.
47. Trudeau MC, Warmke JW, Ganetzky B, Robertson GA (1995). hERG, a human inward rectifier in the voltage-gated potassium channel family. Science 269 : 92 95.
48. Trudeau MC, Warmke JW, Ganetzky B, Robertson GA (1996). hERG sequence correction. Science 272 : 1087.
49. Ulens C, Daenens P, Tytgat J (1999). Norpropoxyphene-induced cardiotoxicity is associated with changes in ion-selectivity and gating of hERG currents. Cardiovasc Res 44 : 568 578.
50. Vandenberg JI, Varghese A, Lu Y, Bursill JA, Mahaut-Smith MP, Huang CL (2006). Temperature dependence of human ether-a-go-go-related gene K+ currents. Am J Physiol Cell Physiol 291 : C165 C175.
51. Webster R, Leishman D, Walker D (2002). Towards a drug concentration effect relationship for QT prolongation and torsades de pointes. Curr Opin Drug Discov Devel 5 : 116 126.
52. Weininger D (1988). SMILES, a chemical language and information system. 1. Introduction to methodology and encoding rules. J Chem Inf Comput Sci 28 : 31 36.
53. Weininger D, Weininger JL (1989). Algorithm for generation of unique SMILES notation. J Chem Inf Comput Sci 29 : 97 101.
54. Witchel HJ, Dempsey CE, Sessions RB, Perry M, Milnes JT, Hancox JC et al. (2004). The low-potency, voltage-dependent hERG blocker propafenone - molecular determinants and drug trapping. Mol Pharmacol 66 : 1201 1212.
55. Yang P, Kanki H, Drolet B, Yang T, Wei J, Viswanathan PC et al. (2002). Allelic variants in long-QT disease genes in patients with drug-associated torsades de pointes. Circulation 105 : 1943 1948.
56. Yang T, Kanki H, Roden DM (2003). Phosphorylation of the IKs channel complex inhibits drug block. Novel mechanism underlying variable antiarrhythmic drug actions. Circulation 108 : 132 134.
57. Zhang S, Zhou Z, Gong Q, Makielski JC, January CT (1999). Mechanism of block and identification of the verapamil binding domain to hERG potassium channels. Circ Res 84 : 989 998.